中医药治疗动脉粥样硬化的研究进展：聚焦于脂蛋白磷脂酶A2

WANG Lu-ming; ZHANG Wen-lan; LYU Nuan; SUO Yan-rong; YANG Lin; YU Bin; JIANG Xi-juan

doi:10.1007/s11655-023-3611-6

Your Location：

Home >

Browse articles >

中医药治疗动脉粥样硬化的研究进展：聚焦于脂蛋白磷脂酶A2

Review | Updated：2024-02-22

- 中医药治疗动脉粥样硬化的研究进展：聚焦于脂蛋白磷脂酶A2
- Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2
- 中国结合医学杂志（英文版） 2024年30卷第3期页码：277-288
- Affiliations：
  
  1.School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin (301617), China
  2.Department of Traditional Chinese Medicine, Ganzhou People's Hospital, Ganzhou, Jiangxi Province (341000), China
  3.School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin (301617), China
- Author bio：
  
  Prof. YU Bin, E-mail: yubin_771115@hotmail.com
- Funds：
  
  the National Natural Science Foundation of China(82074211;81873130;8216140470);Graduate Research Innovation Project of Tianjin University of Traditional Chinese Medicine(YJSKC-20221026;YJSKC-20221029);2021 Annual Graduate Students Innovation Fund of School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine(ZXYCXLX202116;ZXYCXLX202101)
- DOI：10.1007/s11655-023-3611-6
  中图分类号：
- 纸质出版日期：2024-03，
  
  网络出版日期：2023-12-07，
  
  录用日期：2023-04-24
Scan for full text
中医药治疗动脉粥样硬化的研究进展：聚焦于脂蛋白磷脂酶A2[J]. 中国结合医学杂志（英文版）, 2024,30(3):277-288.

WANG Lu-ming, ZHANG Wen-lan, LYU Nuan, et al. Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2[J]. Chinese Journal of Integrative Medicine, 2024,30(3):277-288.
中医药治疗动脉粥样硬化的研究进展：聚焦于脂蛋白磷脂酶A2[J]. 中国结合医学杂志（英文版）, 2024,30(3):277-288. DOI： 10.1007/s11655-023-3611-6.

WANG Lu-ming, ZHANG Wen-lan, LYU Nuan, et al. Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2[J]. Chinese Journal of Integrative Medicine, 2024,30(3):277-288. DOI： 10.1007/s11655-023-3611-6.

摘要

动脉粥样硬化作为一种严重的心血管疾病

其特点为慢性炎症和氧化应激的发生

常严重威胁人类健康. 有研究表明

磷脂酶家族的成员: 脂蛋白相关磷脂酶 A2的水平升高是导致动脉粥样硬化的原因之一. 脂蛋白磷脂酶A2与多种脂蛋白密切相关

研究发现

在动脉粥样硬化中其主要通过水解氧化磷脂生成溶血磷脂促进炎症反应和氧化应激. 此外

斑块局部的脂蛋白磷脂酶A2还可促进斑块内巨噬细胞的凋亡

进而使斑块变为不稳定斑块. 本综述对近年来中医药通过降低脂蛋白磷脂酶A2的水平治疗动脉粥样硬化的相关研究进行了汇总

以期对动脉粥样硬化的相关的实验研究和临床应用提供帮助.

Abstract

As a serious cardiovascular disease

atherosclerosis (AS) causes chronic inflammation and oxidative stress in the body and poses a threat to human health. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 (PLA2) family

and its elevated levels have been shown to contribute to AS. Lp-PLA2 is closely related to a variety of lipoproteins

and its role in promoting inflammatory responses and oxidative stress in AS is mainly achieved by hydrolyzing oxidized phosphatidylcholine (oxPC) to produce lysophosphatidylcholine (lysoPC). Moreover

macrophage apoptosis within plaque is promoted by localized Lp-PLA2 which also promotes plaque instability. This paper reviews those researches of Chinese medicine in treating AS via reducing Lp-PLA2 levels to guide future experimental studies and clinical applications related to AS.

关键词

脂蛋白磷脂酶A2动脉粥样硬化炎症氧化应激细胞凋亡中医药治疗

Keywords

lipoprotein-associated phospholipase A2atherosclerosisinflammationoxidative stressapoptosisChinese medicine

references

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Quercetin Attenuates Atherosclerosis via Modulating Apelin Signaling Pathway Based on Plasma Metabolomics

Network Pharmacology and Experimental Validation to Explore Mechanism of Tetrahydropalmatine on Acute Myocardial Ischemia

Guanxin Ⅴ Relieves Ventricular Remodeling by Inhibiting Inflammation: Implication from Virtual Screening, Systematic Pharmacology, Molecular Docking, and Experimental Validation

Danhong Injection Up-Regulates miR-125b in Endothelial Exosomes and Attenuates Apoptosis in Post-Infarction Myocardium

Protective Effects and Potential Mechanism of Tongxinluo on Mice with Thromboangiitis Obliterans Induced by Sodium Laurate^*